

গণপ্রজাতন্ত্রী বাংলাদেশ সরকার
ঔষধ প্রশাসন অধিদপ্তর
ঔষধ ভবন, মহাখালী, ঢাকা-১২১২
www.dgda.gov.bd

নং-ডিজিডিএ/এলাট-নোটিশ/এমসি-১৬/২০১৯/ ৭৭৬


তারিখঃ ২৪/০৫/২০২১

-:অফিস আদেশ:-

ঔষধ প্রশাসন অধিদপ্তরের মাঠ পর্যায়ের সকল কর্মকর্তাদের জানানো যাচ্ছে যে, বিশ্ব স্বাস্থ্য সংস্থা (WHO) সম্প্রতি মেডিক্যাল প্রোডাক্ট এলাট N° 4/2021- এ এই মর্মে সতর্ক করেছে যে, Gilead কর্তৃক উৎপাদিত remdesivir injection 100mg/20ml(5mg/ml) এর ব্যাচ EN2005A2-B এবং EN2009D7-Q Mexico এর বাজারে নকল (Falsified) হিসাবে পাওয়া গিয়েছে। উল্লেখ্য যে, EN2005A2-B ব্যাচ এর remdesivir injection 100mg/20ml(5mg/ml) ঔষধটির মেয়াদউত্তীর্ণের তারিখ সঠিক নয় এবং ব্যাচ EN2009D7-Q এর remdesivir injection 100mg/20ml(5mg/ml) ঔষধটি Gilead কর্তৃক উৎপাদিত নয়।


Product Name	remdesivir injection100mg/20ml (5mg/ml)	
Stated manufacturer	GILEAD	
Stated active ingredient	remdesivir	
Batch / Lot	EN2005A2-B	EN2009D7-Q
Exp date	06/2023	Not Stated
Identified in	Mexico	Mexico
Packaging language	English	Not Stated

Table 2: Photographs of products subject of WHO Medical Product Alert N°4/2021



এমতাবস্থায়, উপরোল্লিখিত ঔষধটিতে বাজারে পাওয়া গেলে তা বিধি মোতাবেক জব্দ করে প্রয়োজনীয় ব্যবস্থা গ্রহণের জন্য এতদ্বারা নির্দেশ প্রদান করা হলো।

সংযুক্তিঃ ০২ (২২) পাতা।


মোঃ আসরাফ হোসেন
উপপরিচালক
ঔষধ প্রশাসন অধিদপ্তর, ঢাকা।
ফোনঃ ০২২২২২-৮০৮০৩
Email: dgda.gov@gmail.com

Ref. RPQ/REG/ISF/Alert N°4 2021

August 2021

Medical Product Alert N° 4/2021

Falsified Remdesivir identified in WHO region of the Americas

Alert Summary

This WHO Medical Product Alert refers to two batches of falsified remdesivir injection 100mg/20ml (5mg/ml) identified in the WHO Region of the Americas and reported to WHO in July 2021. These products claim to be manufactured by GILEAD. However, GILEAD has confirmed that the remdesivir products listed in this alert are falsified and were not manufactured by them. These falsified products have been reported at patient level (including at a hospital) in Mexico and are illicitly supplied on the internet.

Remdesivir is a broad-spectrum antiviral medication that was approved or authorized for emergency use to treat COVID-19 in several countries. In November 2020, WHO updated a conditional recommendation against remdesivir in hospitalized patients with COVID-19. This recommendation is part of the WHO Therapeutics and COVID-19: living guideline and states "A conditional recommendation is issued when the evidence around the benefits and risks of an intervention are less certain. In this case, there is a conditional recommendation against the use of remdesivir. This means that there isn't enough evidence to support its use."

The products identified in this alert are confirmed as falsified on the basis that they deliberately / fraudulently misrepresent their identity, composition, or source. The composition of the vials is currently unknown and laboratory analyses are to be conducted.

- Batch EN2005A2-B: the batch number and the expiry date (06/2023) do not correspond to any remdesivir manufactured by GILEAD.
- Batch EN2009D7-Q: the batch number does not correspond to any remdesivir manufactured by GILEAD.

Table 1: Products subject of WHO Medical Product Alert N°4/2021

ProductName	remdesivir injection 100mg/20ml (5mg/ml)	
Stated manufacturer	GILEAD	
Stated active ingredient	remdesivir	
Batch / Lot	EN2005A2-B	EN2009D7-Q
Exp date	06/2023	Non stated
Packaging language	English	Non stated
Identified in	Mexico	Mexico

For photographs of the above products, please refer to Table 2 on page 2 of this Alert.



Advice to regulatory authorities and the public

WHO requests increased vigilance within the supply chains of countries and regions likely to be affected by these falsified products. Increased vigilance should include hospitals, clinics, health centres, wholesalers, distributors, pharmacies, and any other suppliers of medical products.

All medical products must be obtained from authorized/licensed suppliers. The products' authenticity and physical condition should be carefully checked. Seek advice from a healthcare professional in case of doubt.

If you are in possession of the above falsified products, please do not use them.


If you have used these products, or you suffered an adverse reaction/event having used these products, you are advised to seek immediate medical advice from a qualified healthcare professional, and to report the incident to the National Regulatory Authorities / National Pharmacovigilance Centre.

National regulatory / health authorities are advised to immediately notify WHO if these falsified products are discovered in their country. If you have any information concerning the manufacture, distribution, or supply of these products, please contact rapidalert@who.int

Table 2: Photographs of products subject of WHO Medical Product Alert N°4/2021

Falsified remdesivir injection 100mg/20ml (5mg/ml) identified in Mexico

Batch EN2005A2-B



WHO Global Surveillance and Monitoring System for Substandard and Falsified Medical Products

For more information, please visit our [website](https://www.who.int/teams/global-drug-regulatory-services)

Email: rapidalert@who.int